Actively Recruiting
Validation of Tumor-Infiltrating T-Cells as a Biomarker for Advanced Epithelial Ovarian Cancer
Led by Gynecologic Oncology Group · Updated on 2017-05-05
174
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
G
Gynecologic Oncology Group
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying tumor tissue samples from patients who had surgery for advanced stage III or stage IV ovarian epithelial cancer. The study aims to see if tumor-infiltrating T lymphocytes (TILs) can help predict how long patients live without their cancer getting worse and their overall survival. This research may improve understanding of how the immune system affects treatment outcomes in ovarian cancer. The study uses previously collected tumor tissue samples from patients who had either optimal or suboptimal cytoreductive surgery. These samples are analyzed in the laboratory using immunohistochemistry and double immunofluorescence assays to detect TILs. Patients are grouped based on the extent of their surgery results to validate the predictive value of TILs for progression-free and overall survival. Participants have already undergone surgery and chemotherapy as part of other clinical trials, and their tissue samples and clinical data are used for analysis. Researchers review demographic, follow-up, and disease measurements to evaluate the role of TILs. The main outcomes studied are survival curves showing progression-free survival and overall survival. This observational study involves no new treatments or interventions for participants.
CONDITIONS
Brief Title
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of stage III or IV ovarian epithelial cancer
- Enrollment in Gynecologic Oncology Group (GOG)-0136 and a GOG front-line platinum/taxol chemotherapy trial
- Availability of fixed and paraffin-embedded tissue from primary surgery
- Patients who had either optimal or suboptimal cytoreductive surgery
- Adequate demographic and follow-up data collected
- Measurable or nonmeasurable disease
- Demographic and follow-up data available
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Time required to analyze samples
Previously collected tumor tissue samples are analyzed for tumor-infiltrating lymphocytes (TIL) using immunohistochemistry and double immunofluorescence assays.
No additional visits required for sample analysis
Duration - Ongoing until study completion
Participants are followed over time to assess progression-free survival and overall survival based on tumor tissue analysis.
Follow-up visits as part of routine care
Trial Site Locations
Total: 1 location
1
Gynecologic Oncology Group
Philadelphia, Pennsylvania, United States, 19103
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here